七月 2026
- Home
- Credo Diagnostics Biomedical
七月 2026的Credo Diagnostics Biomed...市场份额分析
Privacy Policy This Privacy Policy (“Policy”) describes how Credo Diagnostics Biomedical Pte. Ltd. including its subsidiaries and affiliates, (together referred to as “Credo Diagnostics”) handles the personal information that you provide to on websites controlled by Credo Diagnostics which link to this Policy (together referred to as “Website(s)”). Your use of Website(s) is subject to […]
Credo Diagnostics Biomedical(包含公司地区分支机构)
查看更多网站流量和参与度信息- credodxbiomed.com
Credo Diagnostics Biomedical收入截至 七月 2026为 2M - 5M
Credo Diagnostics Biomedical主要域名产生的收入
3 年中Credo Diagnostics Biomedical主要域名的收入
Credo Diagnostics Biomedical主要域名的收入
Credo Diagnostics Biomedical热门域名的总访问量
了解Credo Diagnostics Biomedical市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Credo Diagnostics Biomedical热门域名的平均访问时长
分析Credo Diagnostics Biomedical参与度指标。
过去 3 个月的平均访问时长
子公司明细
Credo Diagnostics Biomedical热门域名的平均页面浏览量
了解Credo Diagnostics Biomedical如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Credo Diagnostics Biomedical 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Credo Diagnostics Biomedical Pte. Ltd launched VitaPCR TM on Jan 1st '19.Founded in 2011, Credo Diagnostics launched the VitaPCR TM in 2019, a revolutionary molecular biology platform capable of detecting infectious pathogens (including the SARS-CoV-2 responsible for Covid-19, influenza and RSV viruses) by Polymerase Chain Reaction (PCR) methodology in only 20 minutes.
一月 13, 2023阅读更多
查看 Credo Diagnostics Biomedical 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
